Citation: Djambazov SN, Vekov TY, Mekov EV, Slavchev GS, Petkov RE, Kostadinov DT, Konteva LT. ALK mutation status in EGFR-negative non-small-cell lung cancer patients in Bulgaria. Folia Med (Plovdiv) 2018;60(3): 397-401. doi: 10.2478/folmed-2018-0010 Background: Patients with non-small-cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) rearrangement mutation are found to be 3-13%. Aim: To evaluate the prevalence of ALK mutations in EGFR-negative NSCLC patients in Bulgaria. Materials and methods: One hundred and thirty-two patients with EGFR-negative NSCLC were examined for ALK mutation analysis between January and June 2016. Data were obtained from patients' register of four major oncological hospitals in Bulgaria. Results: Data were available for 124 (93.9%) patients, tumor mass was insuffi cient for analysis in 8 (6.1%) patients. Most of the patients were with adenocarcinoma (82 patients, 62.1%); 11 patients (8.3%) were with squamous histology and 2 patients (1.5%) were with other type of NSCLC. Histology data were missing in 37 patients (28.0%). ALK mutation was confi rmed in 5 patients (3.8%), 119 (90.2%) patients had ALK wild type. ALK positive patients were with adenocarcinoma (n=3), squamous cell carcinoma (n=1) and other type (n=1) NSCLC. All ALK mutations were observed in never smokers (n=3) and former smokers (n=2).
Lung cancer is the leading cause of death from cancer worldwide with 14.1 million people diagnosed per year and mortality of 8.2 million annual deaths. 1, 2 The disease remains the most common cancer in men worldwide. Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer, making up 80-85% of all cases. Chemotherapeutic regimens are gold standard for treatment of advanced NSCLC but the clinical outcomes are discouraging and the impact on median overall survival (OS) barely reaches 12 months and the fi ve-year survival rate is 16%. 3, 4 Lung cancer is the most common malignancy in men and the fi fth most common in women in Bulgaria. 5 It accounts for 19 .3% of all newly diagnosed cancer cases in men and for 5.3% in women. The crude incidence rate is 95.1 per 100 000 men and 21.4 per 100 000 women. 73.2% of all cancer cases are morphologically confi rmed. The most frequently diagnosed lung cancer type is squamous cell carcinoma (50.2%), followed by adenocarcinoma (21.9%), and small cell carcinoma (15.5%). 5 Cancer management has undergone signifi cant changes over the past decade. New targets and driver oncogenes (which initiate and maintain malignancy) have been identifi ed. The gained information for oncogenes, such as the epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene (KRAS), v-raf murine sarcoma viral oncogene homolog B1, anaplastic lymphoma kinase (ALK), and the development of new drugs that specifi cally target mutations in them have led to improvements in survival without signifi cant toxicities. 6 The prevalence of ALK rearrangement mutation
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in NSCLC patients is found to be 3%-13%. [7] [8] [9] [10] [11] [12] [13] [14] [15] The ALK gene is found in the short arm of chromosome 2 and encodes a tyrosine kinase. ALK mutations are caused by fusion between ALK gene and echinoderm microtubule-associated protein-like 4 (EML4) gene. This abnormal gene fusion leads to the production of a protein (EML4-ALK) that appears, in many cases, to promote and maintain the malignant behavior of the cancer cells. 14 There is no data on ALK mutation rate in Bulgaria. The presence of EGFR, ALK or any driver mutation is a prerequisite for targeted therapy and thus needs to be accurately assessed in NSCLC. [16] [17] [18] Because EGFR and ALK mutations are mutually exclusive, patients with ALK mutation are not thought to benefi t from EGFR-targeting tyrosine kinase inhibitor's therapy. Instead, a treatment with an ALK inhibitor (crizotinib, ceritinib) is indicated. [19] [20] [21] The aim of the current study is to estimate the prevalence of ALK mutations in EGFR-negative patients with NSCLC in Bulgaria.
MATERIALS AND METHODS

PATIENTS
One hundred and thirty-two patients with EGFRnegative NSCLC were examined for ALK mutation analysis between January and June 2016. Data were obtained from patients' register of four major oncological hospitals in Bulgaria (Serdika Hospital, Sofi a; Central Oncological Hospital, Plovdiv; Nadezhda Hospital, Sofi a; Tsaritsa Yoanna University Hospital, ISUL, Sofi a).
Data on patients' characteristics were collected including age, gender, smoking status, stage and histology, if available. All patients were staged according to seventh revision of TNM classifi cation for NSCLC.
All patients with NSCLC were tested for EGFR mutation (Cobas). EGFR-negative NSCLC samples were subsequently tested for presence of ALK mutations (EML4-ALK Fusion Gene Detection Assay; AmyoDx). 
RESULTS
Data were available for 124 patients; tumor mass was insuffi cient for analysis in 8 (6.1%) patients. ALK mutation was confi rmed in 5 patients (3.8%), 119 (90.2%) patients were diagnosed with ALK wild type (Fig. 1) . ALK mutation prevalence only in adenocarcinoma is 3.9% (3/76).
Baseline characteristics of the population are summarized in Table 1 ALK positive patients had adenocarcinoma (n=3), squamous cell carcinoma (n=1) and another type (n=1) of NSCLC. All ALK mutations were observed in never smokers (n=3) and former smokers (n=2). ALK mutations do not show difference between the genders (60 vs. 66.4%, p=0.609).
DISCUSSION
ALK rearrangement occurs in 3% to 13% of NSCLC patients and it is more prevalent in never/ former smokers patients with adenocarcinomas. This study showed ALK mutation prevalence of 3.8% which tends to be low compared to other stud- ies. [7] [8] [9] [10] [11] [12] [13] [14] [15] ALK mutation prevalence in adenocarcinoma is similar -3.9%. However, ALK mutations occur predominantly, but not only in adenocarcinoma. Therefore, further analysis is required for identifying subgroups of patients which may benefi t for this investigation, i.e. in the unusual case of relatively young non-or ex-smoker with squamous cell carcinoma, as this study suggests.
ALK mutation status is not related to gender, which could be partially explained with lack of signifi cant difference in smoking status and age between males and females (all p>0.05). The ALK fusion oncogene in patients with NSCLC is strongly associated with a history of never or light smoking. 13, 22 The present study also confi rms these observations. The patients with ALK rearrangements tended to be younger and they have predominantly adenocarcinoma which is also reported in other studies. 19 An ALK inhibitor is preferred as a fi rst-line therapy for patients with ALK positive NSCLC. It is associated with prolongation in progression-free survival (PFS) and improved response rate and quality of life. 23 The present study did not report increased OS, but other studies reported 1-year survival of 74.8% 24 and median OS of 49.4 months with PFS 8.2 months. 25 This study determines the ALK mutation prevalence in a large number of patients, similar to this of other studies. This is the fi rst study in Bulgaria on this subject. Moreover, the sample from multiple centers makes it representative and gives higher confi dence of the results' generalizability. The demographic characteristics provide useful information for identifying subgroups of patients with highest probability of ALK mutations (for example non-and ex-smokers) as well as those with lower probability (i.e. current smokers). The limitations of this study are related to the missing information. Since the data were obtained from registers, some of the information was not available and this resulted in lower statistical power of some of the analyses.
CONCLUSION
Our study showed 3.8% prevalence of ALK mutation in EGFR-negative NSCLC patients and 3.9% in patients with adenocarcinoma which tends to be low. However, most of the patients with ALK mutation were with adenocarcinoma. ALK rearrangements tend to happen in younger patients and did not correlate with gender. The presence of EGFR, ALK or other driver mutation is a prerequisite for targeted therapy and thus needs to be accurately assessed in NSCLC. The identifi cation of ALK mutation in patients with advanced NSCLC is associated with better prognosis if target therapy is started.
